Promus PREMIER™

Everolimus-Eluting Platinum Chromium Coronary Stent System

PLATINUM Workhorse Trial

Platinum Chromium Everolimus-Eluting Clinical Experience.

Study Objective: Evaluate the safety and effectiveness of the Promus PtCr EES Stent System* for the treatment of patients with up to 2 de novo lesions ≤ 24 mm in length; ≥ 2.50 mm to ≤ 4.25 mm in diameter compared to the Xience CoCr EES.

Study Design: Prospective, Randomized, Controlled, Non-inferiority, Multicenter.

Platform Influences Outcomes

The PLATINUM Workhorse Trial 5-Year data reinforce the influence that Platinum Chromium (PtCr) stent alloy has on outcomes. The Promus PREMIERTM Stent's PtCr alloy, combined with a unique customized architecture, provide exceptional results.

Numerically Lower Ischemia-Driven TLR1

5-Year Clinical Results

Numerically Lower Ischemia-Driven TLR

Numerically Lower Event Rates1

5-Year Clinical Results

Numerically Lower Event Rates

Significant Reduction In Unplanned Bail-out Stenting = $116 Savings / Procedure2, 3

1-Year Results

Significant Reduction In Unplanned Bail-out Stenting = $116 Savings / Procedure

PREMIER Architecture.
PREMIER Outcomes.


Features the only customized Platinum Chromium Stent architecture, the market-leading Everolimus drug and PVDF-HFP polymer combination and an enhanced catheter to provide Premier outcomes.

Top